Article

Autoimmunity in schizophrenia: a review of recent findings.

University of Pittsburgh Medical School, Department of Psychiatry, Pennsylvania 15213.
Annals of Medicine (Impact Factor: 4.73). 11/1993; 25(5):489-96. DOI: 10.3109/07853899309147317
Source: PubMed

ABSTRACT The pathophysiology of psychotic and other symptoms in schizophrenia remains a mystery despite decades of research. Even though it has been suspected for many years that autoimmune mechanisms may play a role in the pathophysiology of schizophrenia, firm evidence for this hypothesis has been lacking. Our studies, over the last 10 years, have revealed that a subgroup of schizophrenics have several significant immunological abnormalities, including increased prevalence of autoimmune diseases and of antinuclear antibodies (ANA) and anticytoplasmic antibodies (ACA), decreased lymphocyte interleukin-2 (IL-2) production, increased serum IL-2 receptor concentration, increased serum IL-6 concentration, and an association with HLA antigens. These findings are characteristic of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and insulin-dependent diabetes mellitus. We also found that some schizophrenics have antibodies to hippocampal antigens (AHA) in their serum, together with lowered IL-2 production. None of the above findings can be interpreted as definitely confirming the role of autoimmunity in schizophrenia. Nevertheless, taken together, the recent evidence points towards the existence of a subgroup of schizophrenics who have immunological findings consistent with that hypothesis. Further studies directed at finding the brain antigens targeted by the immune system in these patients, and longitudinal studies correlating clinical and immune changes over time, are needed.

0 Bookmarks
 · 
110 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary Infection, inflammation and autoimmune processes are accompanied by disturbances of well-being, psychosocial functioning, cognitive performance, and behavior. Here we review those studies that have investigated the effects of infectious diseases or experimental immunomodulation on sleep and sleepiness in humans. Naturalistic studies in infected humans are scanty and have yielded conflicting results. In most of the experimental studies bacterial endotoxin was injected intravenously to model various aspects of infection including the release of inflammatory cytokines. These studies show that human sleep-wake behavior is very sensitive to host defense activation. Small amounts of endotoxin that neither affect body temperature nor neuroendocrine systems, but slightly stimulate the secretion of inflammatory cytokines, promote non-rapid-eye-movement (nonREM) sleep amount and intensity. Febrile host responses, in contrast, go along with prominent sleep disturbances. According to the present knowledge tumor necrosis factor-α (TNF-α) is most probably a key mediator of these effects, although it is likely that disturbed sleep during febrile host responses involves endocrine systems as well. Hence, enhanced and disturbed sleep during infections disease might be caused by different degrees of host defense activation. Moreover, there is preliminary evidence from human studies suggesting that inflammatory cytokines such as TNF-α not only mediate altered sleep-wake behavior during infections, but in addition are involved in physiological sleep regulation and in hypnotic effects of established sedating drugs. German Zusammenfassung Infektionen, Entzündungen und Autoimmunprozesse sind von erheblichen Störungen des Wohlbefindens, der beruflichen und sozialen Leistungsfähigkeit, der kognitiven Funktionen und des Verhaltens begleitet. Insbesondere das Schlaf-Wach-Verhalten reagiert auf immunologische Prozesse sehr sensitiv. In der vorliegenden Übersichtsarbeit wird der gegenwärtige Stand des Wissens zum Einfluss einerseits von Infektionen und andererseits experimenteller Immunmodulation auf Schlaf und Schläfrigkeit beim Menschen dargestellt. Das Wissen über den Schlaf im Rahmen von Infektionen ist spärlich und zum Teil widersprüchlich. In den meisten der experimentellen Studien wurde der Einfluss bakteriellen Endotoxins untersucht, das eine Vielzahl pathophysiologischer Aspekte akuter Infektionen imitiert, einschließlich der Freisetzung inflammatorischer Zytokine. Diese Studien zeigen, dass das menschliche Schlaf-Wach-Verhalten auf eine Aktivierung der primären Wirtsantwort sehr sensibel reagiert. Geringe Mengen Endotoxin, die weder die Körpertemperatur noch neuroendokrine Systeme beeinflussen, aber in diskreter Weise die Freisetzung inflammatorischer Zytokine stimulieren, führen zu einer Zunahme der nonREM-Schlafmenge und Intensität. Größere Mengen Endotoxin hingegen, die prominente febrile Reaktionen induzieren und eine ausgeprägte neuroendokrine Aktivierung, gehen mit einer erheblichen ­Störung des Nachtschlafes einher. Nach dem gegenwärtigen Wissensstand ist Tumor Nekrose Faktor-α (TNF-α) wahrscheinlich der zentrale Mediator dieser Effekte, wobei es aber wahrscheinlich ist, dass die erhebliche Schlafstörung, die während fieberhafter Wirts­antworten auftritt, auch durch die endokrine Aktivierung mit bedingt ist. Diese experimentelle Datenlage macht es verständlich, warum Infektionen beim Menschen sowohl mit einer Zunahme der Schlafmenge, als auch mit erheblichen Schlafstörungen einher gehen können; denn je nach dem Ausmaß der Wirtsantwort und dem Stadium der Infektion dürfte die Menge an zirkulierenden inflammatorischen Zytokinen und die endokrine Aktivierung sehr unterschiedlich sein. Aus weiteren Humanstudien gibt es erste Hinweise darauf, dass inflammatorische Zytokine wie TNF-α nicht nur die Veränderung des Schlaf-Wach-Verhaltens im Rahmen von Infektionen vermitteln, sondern dass diese Zytokine zudem eine Rolle in der physiologischen Schlafregulation spielen, und dass sie möglicherweise die hypnotische Wirkung bereits etablierter und zugelassener Medikamente mediieren.
    Somnologie - Schlafforschung und Schlafmedizin 01/2000; 4(2).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many lines of findings support the hypothesis of the inflammation-related pathways in the multifactorial pathogenesis of schizophrenia (SZ). Interleukin-10 (IL-10), a potential anti-inflammatory cytokine, was found to be altered in chronic patients with SZ. The aim of this study was to assess the serum levels of IL-10 in first-episode and drug-naïve (FEDN) patients with SZ and its relationships with the psychopathological parameters. Serum IL-10 levels were analyzed using established procedures in 128 FEDN patients with SZ and 62 healthy controls. Schizophrenia symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) with cognitive factor derived from the five factor model of the PANSS. Compared to the healthy controls, the patients exhibited a significant decrease in IL-10 levels. Serum IL-10 was inversely correlated with the PANSS negative symptom, as well as with the PANSS cognitive factor subscores in patients. Our results suggested that decreased IL-10 may be implicated in the negative symptom and cognitive impairment at the acute stage of schizophrenia episode.
    Schizophrenia Research 06/2014; · 4.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A century of research into the aetiology of schizophrenia has not been substantially productive. However, in recent years, there has been a resurgence of interest in a possible autoimmune involvement in a subset of patients with schizophrenia. Here, Dr Pandarakalam discusses the evidence.
    Progress in Neurology and Psychiatry 01/2013; 17(1).